论文部分内容阅读
目的探讨通心络胶囊治疗冠心病心绞痛的临床疗效及安全性。方法选取徐州市贾汪区人民医院2016年1月—2017年1月收治的冠心病心绞痛患者90例,随机分为对照组和观察组,各45例。对照组患者给予常规治疗,观察组患者在对照组基础上给予通心络胶囊治疗,两组患者均持续治疗4周。比较两组患者的临床疗效、心电图改善情况,观察患者不良反应发生情况。结果观察组患者治疗总有效率高于对照组(P<0.05)。观察组患者心电图改善情况优于对照组(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论采用通心络胶囊治疗冠心病心绞痛的临床疗效确切,可有效改善患者的心功能,且安全性好。
Objective To investigate the clinical efficacy and safety of Tongxinluo capsule in the treatment of angina pectoris of coronary heart disease. Methods Ninety patients with coronary heart disease and angina pectoris who were admitted to Jiawang District People’s Hospital of Xuzhou from January 2016 to January 2017 were randomly divided into control group and observation group, with 45 cases in each group. Patients in the control group were given routine treatment. Patients in the observation group were given Tongxinluo capsule on the basis of the control group, and both groups were treated for 4 weeks. Compare the clinical curative effect of the two groups of patients, improve electrocardiogram and observe the occurrence of adverse reactions in patients. Results The total effective rate of observation group was higher than that of control group (P <0.05). The improvement of electrocardiogram in observation group was better than that in control group (P <0.05). Two groups of patients during the treatment did not appear serious adverse reactions. Conclusion Tongxinluo Capsule is effective in treating patients with coronary heart disease and angina pectoris. It can effectively improve the cardiac function of patients and has good safety.